No PFS Benefit With Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma

Published Date: 16 Sep 2024

Data support that ICI rechallenge should be discouraged in patients with advanced RCC

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

No PFS Benefit With Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma

2.

Glioblastoma treatment breakthrough shows promise

3.

Omicron Infections Are Usually Cleared Up in Immunocompromised Patients.

4.

A novel blood test may enable the early identification of common, fatal cancers.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot